Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 2

3(37.5%)

Phase 4

1(12.5%)

8Total

Phase 3(4)

Phase 2(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01972932Phase 4Terminated

Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea

Role: lead

NCT00941356Phase 2Withdrawn

Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

Role: lead

NCT03239366Phase 2Unknown

A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population

Role: lead

NCT01545037Phase 2Completed

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

Role: lead

NCT01202630Phase 3Suspended

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Role: lead

NCT00328263Phase 3Completed

Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients

Role: lead

NCT00958308Phase 3Completed

Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection

Role: lead

NCT00737412Phase 3Completed

Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults

Role: lead

All 8 trials loaded